Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- JPMorgan (JPM) shares are responding to this morning's early release. 3Q FICC sales and trading revenue missed estimates. It marks the first such decline in more than two years. Still, CEO Jamie Dimon still said "each line of business performed well."
- Wells Fargo (WFC) shares are moving after it reported net interest income for the third quarter that met the average analyst estimate.
- Johnson & Johnson (JNJ) and UnitedHealth (UNH) shares are both moving as they report earnings. J&J raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in the company’s medical device business. UnitedHealth raised its profit outlook for the year after reporting better-than-expected earnings in the third quarter.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- LVMH Moët Hennessy Louis Vuitton SE offered a closer look at the Chinese luxury slump, revealing that sales on the mainland fell by double digits last quarter while the traditionally high-spending consumer group also pulled back overseas.
- BP shares gain as much as 1.6% to touch the highest in more than six months, after the British oil major cut its net debt by around $8 billion, reaching its 2027 target early after surging prices drove windfall profits from energy trading and oil refining.
- Whitbread shares gain as much as 3.6%, to the highest level since March, after the hotel operator reported strong first-half results, including a beat on profit before tax. Analysts broadly expect consensus views on full-year profit before tax to be upgraded, noting robust current trading.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- LVMH Moët Hennessy Louis Vuitton offered a closer look at the deepening Chinese luxury slump this week, revealing that sales on the mainland dropped by double digits in the third quarter while the traditionally high-spending consumer group also pulled back overseas.
- Givaudan shares rise as much as 6.7%, to the highest since July 2025, after the maker of fragrances and flavors reported like-for-like growth that was well ahead of expectations in the third quarter. JPMorgan said this should drive upgrades to EPS expectations.
- Finnair shares jumped after the airline boosted its adjusted Ebit forecast for the full year.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- SK Hynix sank 10% and Samsung Electronics about 8% as the Kospi Index in South Korea — a key barometer of the AI trade — tumbled on concerns of Chinese competition, spurring investors to rotate out of the tech sector.
- Chinese semiconductor stocks are rallying to positive on the day and Chinese banks such as China Construction Bank are performing strongly.
- India settles into its new rally with TCS reporting good earnings as Modi talks up tech, data, and AI power at the Bloomberg New Economy Forum.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market, a look at the notable movers:
On this episode of Stock Movers:

- Shares of Bumble (BMBL) quickly spike as much as 21%, triggering a volatility halt, after the Wall Street Journal reported that the dating app is in advanced talks with Ithaca Holdings to be taken private in a deal that values it at roughly $1 billion.

- Meta Platforms (META) released a new artificial intelligence model called Muse Wonder, which the company claims is a big leap over its predecessors with "frontier capabilities". The model is said to be competitive with OpenAI's ChatGPT and Anthropic PBC's Claude, particularly in coding, financial, or legal questions, and will soon power the subscription version of Meta's personal AI agent Muse. Meta AI Chief Alexandr Wang says the company has tried to differentiate itself from competitors by focusing on big models for broad, consumer uses, and is already working on larger and more scaled models, as well as specialized versions that are efficient enough to deploy at massive scale. Meta’s shares rose as high as 4.7% on the announcement.

- Syndax Pharmaceuticals (SNDX) shares plunge 17% postmarket after the biotech said its MAXPIRe Phase 2 trial of axatilimab failed to meet its primary endpoint of annualized rate of decline in forced vital capacity versus a placebo in idiopathic pulmonary fibrosis, a rare lung disease.
See omnystudio.com/listener for privacy information.